A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarNCT06996782 · readout in 919 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
152estimated
Sites
103
Countries
Belgium, Brazil, China +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-24 | actual | When the study began enrolling |
| Primary completion | 2029-02-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
- Drug: Rilvegostomig — also filed as AZD2936
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: Paclitaxel
- Drug: Nab-paclitaxel
- Drug: Ramucirumab
Primary outcomes
what the primary-completion date above is the date OFPart A and Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
measured Approximately 46 months
Part A: Number of partcipants with dose limiting toxicity (DLT)
measured Approximately 46 months
Part B: Objective response (OR)
measured Approximately 46 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed